Quantum Cyber N.V.

Quantum Cyber N.V., formerly known as Mainz Biomed N.V., is a publicly traded company that has undergone a significant strategic transformation. Originally focused on molecular genetics diagnostics for cancer detection, the company is now pivoting its core business towards the intersection of quantum computing and cybersecurity. Its mission involves building a platform to address emerging threats and opportunities in post-quantum cryptography and zero-trust network architectures. The company's historical headquarters were located in Mainz, Germany.

Prior to its rebranding, Quantum Cyber N.V. developed and commercialized diagnostic solutions such as ColoAlert, a colorectal cancer diagnostic test, and PancAlert, a screening test for pancreatic cancer. Following its strategic shift, the company is evaluating acquisition targets within the quantum computing and cybersecurity sectors. It is also focusing on its pancreatic cancer screening business in the U.S., while considering the sale of its colorectal cancer screening assets and the winding down of its German subsidiary.

In a notable development, Mainz Biomed N.V. officially rebranded to Quantum Cyber N.V., with its Nasdaq ticker symbol changing from MYNZ to QUCY, effective March 12, 2026. This strategic pivot was accompanied by the appointment of Robert P. Liscouski as Chairman of the Board, bringing extensive experience in homeland security, cybersecurity, AI, and quantum computing. Quantum Cyber N.V. has also secured $6 million in private placement financing to support its new strategic direction, aligning its efforts with national cybersecurity frameworks and targeting growth in the quantum and cyber defense sectors.